Rocket Pharmaceuticals (RCKTW) News Today

Rocket Pharmaceuticals, Inc. (RCKT) shares have declined amid safety concerns after a patient death in its Phase II RP-A501 Danon disease gene therapy trial prompted the FDA to impose a clinical hold, and Needham downgraded the stock’s rating.

• Rocket provided an update on its Phase II RP-A501 trial, confirming the FDA pause and ongoing safety investigations.
• Short interest remains negligible, with a days-to-cover ratio of 0.0.
• The stock was featured as a trending ticker alongside CoreWeave and SoundHound in recent market-watch videos.
• Multiple news outlets reported that a patient death in the Danon disease gene therapy study led the FDA to halt the trial.
• Shares tumbled in pre-market trading following the FDA’s clinical hold announcement over the patient death.
• Needham downgraded Rocket’s rating, citing heightened clinical and regulatory risk after the trial pause.